Next Article in Journal
Prevalence of Dietary Supplement Use in Healthy Pre-School Chinese Children in Australia and China
Next Article in Special Issue
Readily Available Sources of Long-Chain Omega-3 Oils: Is Farmed Australian Seafood a Better Source of the Good Oil than Wild-Caught Seafood?
Previous Article in Journal
Nutrients Utilization in Obese Individuals with and without Hypertriglyceridemia
Previous Article in Special Issue
Characterization of Oilseed Lipids from “DHA-Producing Camelina sativa”: A New Transformed Land Plant Containing Long-Chain Omega-3 Oils
Open AccessReview

Omega-3 Index and Cardiovascular Health

1
Preventive Cardiology, Medical Clinic and Poli-Clinic I, Ludwig Maximilians-University Munich, Ziemssenstr. 1, Munich 80336, Germany
2
Omegametrix, Am Klopferspitz 19, Martinsried 82152, Germany
Nutrients 2014, 6(2), 799-814; https://doi.org/10.3390/nu6020799
Received: 20 January 2014 / Revised: 12 February 2014 / Accepted: 13 February 2014 / Published: 21 February 2014
Recent large trials with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the cardiovascular field did not demonstrate a beneficial effect in terms of reductions of clinical endpoints like total mortality, sudden cardiac arrest or other major adverse cardiac events. Pertinent guidelines do not uniformly recommend EPA + DHA for cardiac patients. In contrast, in epidemiologic findings, higher blood levels of EPA + DHA were consistently associated with a lower risk for the endpoints mentioned. Because of low biological and analytical variability, a standardized analytical procedure, a large database and for other reasons, blood levels of EPA + DHA are frequently assessed in erythrocytes, using the HS-Omega-3 Index® methodology. A low Omega-3 Index fulfills the current criteria for a novel cardiovascular risk factor. Neutral results of intervention trials can be explained by issues of bioavailability and trial design that surfaced after the trials were initiated. In the future, incorporating the Omega-3 Index into trial designs by recruiting participants with a low Omega-3 Index and treating them within a pre-specified target range (e.g., 8%–11%), will make more efficient trials possible and provide clearer answers to the questions asked than previously possible. View Full-Text
Keywords: cardiovascular disease; eicosapentaenoic acid; docosahexaenoic acid; omega-3 index; cardiovascular prevention cardiovascular disease; eicosapentaenoic acid; docosahexaenoic acid; omega-3 index; cardiovascular prevention
MDPI and ACS Style

Von Schacky, C. Omega-3 Index and Cardiovascular Health. Nutrients 2014, 6, 799-814. https://doi.org/10.3390/nu6020799

AMA Style

Von Schacky C. Omega-3 Index and Cardiovascular Health. Nutrients. 2014; 6(2):799-814. https://doi.org/10.3390/nu6020799

Chicago/Turabian Style

Von Schacky, Clemens. 2014. "Omega-3 Index and Cardiovascular Health" Nutrients 6, no. 2: 799-814. https://doi.org/10.3390/nu6020799

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop